Compositions and methods for treating cancer

(19)

(11)

EP 2 671 581 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	13.11.2019 Bulletin 2019/46

(45)	Mention of the grant of the patent:
	02.10.2019 Bulletin 2019/40

(21)	Application number: 13178249.2

(22)	Date of filing: 29.03.2004

(51)

International Patent Classification (IPC):

A61K 31/415^(2006.01)
C07D 233/02^(2006.01)
A61K 31/5377^(2006.01)
A61P 35/00^(2006.01)
A61K 47/54^(2017.01)

A61K 31/44^(2006.01)
C07D 401/00^(2006.01)
A61K 31/4166^(2006.01)
B82Y 5/00^(2011.01)
A61K 47/68^(2017.01)

(54)	Compositions and methods for treating cancer Zusammensetzungen und Verfahren zur Behandlung von Krebs Compositions et procédés pour le traitement du cancer

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
	Designated Extension States:
	AL LT LV MK

(30)

Priority:

28.03.2003 US 458845 P
21.04.2003 US 465281 P

(43)	Date of publication of application:
	11.12.2013 Bulletin 2013/50

(60)	Divisional application:
	19200942.1

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	04749522.1 / 1622608

(73)	Proprietor: Molecular Templates, Inc.
	Jersey City, NJ 07311 (US)

(72)	Inventors:
	Matteucci, Mark Portola Valley, CA 94028 (US) Rao, Photon Forster City, CA 94404 (US) Duan, Jian-Xin South San Francisco, CA 94080 (US)

(74)	Representative: J A Kemp LLP
	14 South Square Gray's Inn London WC1R 5JJ London WC1R 5JJ (GB)

(56)

References cited: :

HAY M P ET AL: "A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[5,6,7-trimetho xyindol-2-yl)carbonyl]-1,2-dihydro -3H-benz[e]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, GB, vol. 9, no. 15, 2 August 1999 (1999-08-02) , pages 2237-2242, XP004174167, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(99)00381-9
PARVEEN I ET AL: "2-nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, GB, vol. 9, no. 14, 19 July 1999 (1999-07-19), pages 2031-2036, XP004171631, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(99)00306-6
EVERETT S A ET AL: "Bioreductively-activated prodrugs for targeting hypoxic tissues: elimination of aspirin from 2-nitroimidazole derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, GB, vol. 9, no. 9, 3 May 1999 (1999-05-03), pages 1267-1272, XP004163956, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(99)00171-7
COLE C. ET AL.: "Potential Tumor-Selective Nitroimidazolylmethyluracil Prodrug Derivatives: Inhibitors of the angiogenic Enzyme Thymidine Phosphorylase", J. MED. CHEM., vol. 46, 12 December 2002 (2002-12-12), pages 207-209, XP55089704,
DENNY W A: "NITROREDUCTASE-BASED GDEPT", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL LNKD- DOI:10.2174/1381612023394584, vol. 8, no. 15, 1 January 2002 (2002-01-01), pages 1349-1361, XP008042298, ISSN: 1381-6128

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).